(Il Sole 24 Ore Radiocor) - Milano, 7 mag - The Italian pharmaceutical group Angelini Pharma said that it has reached an agreement to buy the Nasdaq-traded Catalyst Pharmaceuticals for 4.1 billion dollars.

Angelini is offering 31.50 dollars per share in cash. The acquisition is expected to close in the third quarter of 2026.

The deal marks Angelini Pharma's entry into the US market, "reinforcing its long-term commitment to brain health and its dedication to people living with rare diseases," it added.

"Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst's portfolio and exceptional commercial infrastructure with its own expertise and products in brain health to develop a next-generation therapeutic platform in rare diseases. This transaction reinforces the commitment Angelini Pharma has built over recent years through products such as Ontozry and high-profile scientific collaborations. Catalyst's portfolio is expected to significantly strengthen the company's strategic objectives, growing its presence in the US as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe.

Angelini Pharma's continued industrial presence in Italy will remain a strategic asset as a valuable production and scientific center within the combined company's global.

operations," it noted.

(RADIOCOR) 07-05-26 12:34:27 (0416) 5 NNNN